Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Adult
Aged
Aged, 80 and over
Alphapapillomavirus
/ isolation & purification
Cohort Studies
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Immune Checkpoint Proteins
/ blood
Immunomodulation
Immunotherapy
/ methods
Leukocytes, Mononuclear
/ metabolism
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Nivolumab
/ therapeutic use
OX40 Ligand
/ blood
Programmed Cell Death 1 Receptor
/ blood
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
T-Lymphocytes, Regulatory
/ immunology
HNSCC
checkpoint inhibitors
head and neck cancer
immune checkpoints
immunomodulation
immunotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jul 2020
22 Jul 2020
Historique:
received:
17
06
2020
revised:
13
07
2020
accepted:
20
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
5
3
2021
Statut:
epublish
Résumé
Endogenous control mechanisms, including immune checkpoints and immunosuppressive cells, are exploited in the process of tumorigenesis to weaken the anti-tumor immune response. Cancer treatment by chemotherapy or immune checkpoint inhibition can lead to changes of checkpoint expression, which influences therapy success. Peripheral blood lymphocytes (PBL) and tumor-infiltrating lymphocytes (TIL) were isolated from head and neck squamous cell carcinoma (HNSCC) patients (
Identifiants
pubmed: 32707816
pii: ijms21155181
doi: 10.3390/ijms21155181
pmc: PMC7432918
pii:
doi:
Substances chimiques
Immune Checkpoint Proteins
0
OX40 Ligand
0
Programmed Cell Death 1 Receptor
0
TNFSF4 protein, human
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Oncol. 2019 Nov 08;9:1102
pubmed: 31781481
Eur J Med Res. 2010 Aug 20;15(8):337-44
pubmed: 20947470
Nat Rev Immunol. 2006 Aug;6(8):613-8
pubmed: 16868552
J Exp Med. 2005 Oct 3;202(7):885-91
pubmed: 16186187
Br J Haematol. 2013 Aug;162(3):313-25
pubmed: 23691926
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554614
Cancers Head Neck. 2016 Oct 1;1:12
pubmed: 31093342
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Immunol Rev. 2011 Nov;244(1):218-31
pubmed: 22017441
Oncoimmunology. 2012 Aug 1;1(5):735-738
pubmed: 22934265
Clin Cancer Res. 2004 Jun 1;10(11):3755-62
pubmed: 15173082
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
J Clin Med. 2018 Aug 27;7(9):
pubmed: 30150513
Br J Cancer. 2013 Nov 12;109(10):2629-35
pubmed: 24169351
Nat Rev Immunol. 2006 Sep;6(9):671-81
pubmed: 16932752
Nat Med. 2019 May;25(5):759-766
pubmed: 31036879
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Eur Arch Otorhinolaryngol. 2019 May;276(5):1465-1473
pubmed: 30815724
Immunity. 2018 Nov 20;49(5):958-970.e7
pubmed: 30446386
J Thorac Dis. 2017 Sep;9(9):3123-3131
pubmed: 29221287
Immunotherapy. 2016 Nov;8(11):1281-1292
pubmed: 27993089
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Eur J Immunol. 2003 Jan;33(1):119-24
pubmed: 12594840
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Oral Oncol. 2017 Jun;69:33-37
pubmed: 28559018
J Immunother Cancer. 2019 Dec 4;7(1):339
pubmed: 31801611
Oncotarget. 2017 May 2;8(32):52889-52900
pubmed: 28881780
Clin Cancer Res. 2013 Dec 1;19(23):6585-96
pubmed: 24097865
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Immunotherapy. 2019 Dec;11(18):1523-1526
pubmed: 31865873
J Immunol Methods. 2011 Jun 30;369(1-2):59-68
pubmed: 21513715
Br J Cancer. 2005 Mar 14;92(5):913-20
pubmed: 15714205
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593